Interleukin-10 -1082 A/G Promoter Polymorphism in Newly Diagnosed Gastro-Intestinal Malignancies and Its Relation to the Nutritional and Performance Status

Multiple myeloma occurs primarily in elderly patients. Considering the high prevalence of comorbidities, comorbidity is an important issue for the management of myeloma. However, the impact of comorbidity on clinical outcomes has not been fully investigated. We retrospectively analyzed patients with newly diagnosed myeloma. Comorbidities were assessed based on the Charlson comorbidity index (CCI) and the Freiburg comorbidity index (FCI). The CCI is a summary measure of 19 comorbid conditions. FCI is determined by performance status, renal impairment, and lung disease. This study included 127 patients with a median age of 71 years. Approximately half of the patients had additional disorders at the time of diagnosis, and diabetes mellitus was the most frequent diagnosis (18.9%). The most significant factors for prognosis among patient-related conditions were a history of solid cancer and performance status (ECOG ≥ 2). The FCI score was divided into 3 groups (0, 1, and 2-3), and the CCI score was divided into 2 groups (2-3 and ≥4). FCI was a strong prognostic tool for OS (P>0.001) and predicted clinical outcome better than CCI (P=0.059). In conclusion, FCI was more useful than CCI in predicting overall survival in elderly patients with myeloma.

Download Full-text

Selection bias, survival, and brachytherapy for glioma

Journal of Neurosurgery ◽

10.3171/jns.1992.76.2.0179 ◽

1992 ◽

Vol 76 (2) ◽

pp. 179-183 ◽

Cited By ~ 112

Author(s):

Randall C. Florell ◽

David R. Macdonald ◽

William D. Irish ◽

Mark Bernstein ◽

Steven A. Leibel ◽

...

Keyword(s):

Patient Selection ◽

Survival Data ◽

Randomized Trials ◽

Performance Status ◽

Population Based ◽

Newly Diagnosed ◽

Content Type ◽

Promising Treatment ◽

And Performance ◽

The Impact

✓ Interstitial irradiation is a promising treatment for malignant glioma. Longer than expected survival periods following treatment of recurrent tumor have led to the use of brachytherapy as an adjuvant treatment. The impact of patient selection on survival data was studied among candidates for this therapy. Consecutive, conventionally treated adults with newly diagnosed supratentorial tumors were identified retrospectively at a center where experience with glioma is population-based. Based on imaging and performance status, two surgeons and a radiation oncologist designated each patient as either eligible or ineligible for adjuvant brachytherapy. The survival and prognostic factors in the eligible and ineligible groups were analyzed. Overall, the patients eligible for brachytherapy (32% of the series) lived significantly longer than the ineligible patients (16.57 vs. 9.30 months), were younger, and had larger resections and better function. For glioblastoma, 40% of patients were eligible, and lived much longer than those who were ineligible (13.90 vs. 5.80 months). It is concluded that better outcome following adjuvant brachytherapy for glioma is at least in part the result of patient selection. Randomized trials of comparably selected patients will be necessary to demonstrate conclusively that longer survival is also a result of treatment.

Download Full-text

Stage distribution and performance status of newly diagnosed patients in a UK regional mesothelioma centre

Lung Cancer ◽

10.1016/j.lungcan.2014.03.024 ◽

2014 ◽

Vol 85 (1) ◽

pp. 99-100 ◽

Cited By ~ 1

Author(s):

Shahul Khan ◽

Matthew Evison ◽

Mohamed Alaloul ◽

Jayne Holme ◽

Richard Booton ◽

...

Keyword(s):

Performance Status ◽

Newly Diagnosed ◽

Stage Distribution ◽

And Performance

Download Full-text

Improved body weight and performance status and reduced serum PGE2levels after nutritional intervention with a specific medical food in newly diagnosed patients with esophageal cancer or adenocarcinoma of the gastro-esophageal junction

Journal of Cachexia Sarcopenia and Muscle ◽

10.1002/jcsm.12009 ◽

2015 ◽

Vol 6 (1) ◽

pp. 32-44 ◽

Cited By ~ 25

Author(s):

Joyce Faber ◽

Madeleen J. Uitdehaag ◽

Manon Spaander ◽

Sabine van Steenbergen-Langeveld ◽

Paul Vos ◽

...

Keyword(s):

Esophageal Cancer ◽

Body Weight ◽

Performance Status ◽

Nutritional Intervention ◽

Newly Diagnosed ◽

Medical Food ◽

And Performance

Download Full-text

Untreated Patients with Acute Myeloid Leukemia, Age 50–59 Years and Performance Status 2 Should Be as Eligible for Targeted Therapy as Older Patients.

Blood ◽

10.1182/blood.v110.11.2864.2864 ◽

2007 ◽

Vol 110 (11) ◽

pp. 2864-2864

Author(s):

Apostolia M. Tsimberidou ◽

Hagop M. Kantarjian ◽

Stefan Faderl ◽

Sherry Pierce ◽

Emil J. Freireich ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Older Patients ◽

Myeloid Leukemia ◽

Performance Status ◽

Newly Diagnosed ◽

Death Rates ◽

Targeted Treatments ◽

High Death ◽

And Performance ◽

Acute Myeloid

Abstract Background: The early mortality rates in older patients (generally defined as those > 60 years) following standard therapy for acute myeloid leukemia (AML), has spurred numerous trials of “targeted” treatments, typically limited to this age group. Here we examine whether younger patients with Zubrod performance status (PS) 2 might also be candidates for these therapies. Patients and Methods: We reviewed the records of 1841 patients 40 years or older with newly diagnosed AML (no acute promyelocytic leukemia) who received cytarabine-containing therapy at M. D. Anderson from 1980 to 2007. We chose patients with the following pretreatment characteristics because they are conventional criteria for entry onto trials of new therapies: PS 0–2, bilirubin < 2 mg/dL, and creatinine < 2 mg/dL. We calculated death rates by age and PS at 28 and 42 days after initiation of induction therapy. Results: Induction death rates in patients with AML by age and performance status The 28-day death rates in patients age 50–59 years with PS 2 were similar to those in patients ≥ 60 years with PS 0–1, and the 42-day death rates in the patients age 50–59 years with PS 2 were similar to those in patients age 60–79 with PS 0–1. Conclusion: Because of the high death rates following AML therapy in patients age 50–59 with PS 2, these patients should be eligible for targeted treatments now limited to older patients. Age, yrs Performance Status No. of Patients Dead by day 28, % Dead by day 42 % 40–49 0–1 288 7 9 40–49 2 38 5 5 50–59 0–1 405 4 6 50–59 2 85 14 15 60–69 0–1 423 8 11 60–69 2 111 17 17 70–79 0–1 301 12 16 70–79 2 124 23 33 ≥80 0–1 45 13 20 ≥ 80 2 21 38 43

Download Full-text

01 / DEVELOPMENT OF MINI-COMPREHENSIVE GERIATRIC ASSESSMENT FOR THE ELDERLY CANCER PATIENTS BASED ON RELATIONSHIPS BETWEEN COMPREHENSIVE GERIATRIC ASSESSMENT ITEMS AND PERFORMANCE STATUS

10.26226/morressier.5afadd8bf314ac000849b31c ◽

2018 ◽

Author(s):

hun mo ryoo

Keyword(s):

Cancer Patients ◽

Geriatric Assessment ◽

Comprehensive Geriatric Assessment ◽

Performance Status ◽

The Elderly ◽

Elderly Cancer Patients ◽

And Performance

Download Full-text

Prognostic value of blood-based fibrosis biomarkers in patients with metastatic colorectal cancer receiving chemotherapy and bevacizumab

Scientific Reports ◽

10.1038/s41598-020-79608-0 ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

Neel I. Nissen ◽

Stephanie Kehlet ◽

Mogens K. Boisen ◽

Maria Liljefors ◽

Christina Jensen ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Collagen Type ◽

Performance Status ◽

Drug Uptake ◽

Collagen Type Iii ◽

Serum Samples ◽

Type Iii ◽

Poor Treatment ◽

And Performance

AbstractA desmoplastic colorectal cancer stroma, characterized by excess turnover of the cancer-associated fibroblast derived collagens type III and VI, can lead to reduced drug-uptake and poor treatment response. We investigated the association between biomarkers of collagen type III and VI and overall survival (OS) in patients with metastatic colorectal cancer (mCRC). Serum samples were collected from 252 patients with mCRC prior to treatment with bevacizumab and chemotherapy. Serum concentrations of biomarkers reflecting formation of collagen type III (PRO-C3) and VI (PRO-C6) and degradation of collagen type VI (C6M and C6Mα3) were determined by ELISA. The biomarkers were evaluated for associations with OS, individually, combined, and after adjusting for carcinoembryonic antigen (CEA), lactate dehydrogenase (LDH) and performance status (PS). High baseline levels (> median) of each collagen biomarker were significantly associated with shorter OS (PRO-C3: HR = 2.0, 95%CI = 1.54–2.63; PRO-C6: HR = 1.6, 95%CI = 1.24–2.11; C6M: HR = 1.4, 95%CI = 1.05–1.78; C6Mα3: HR = 1.6, 95%CI = 1.16–2.07). PRO-C3 and PRO-C6 remained significant after adjustment for CEA, LDH and PS. Weak correlations were seen between the collagen biomarkers (r = 0.03–0.59) and combining all improved prognostic capacity (HR = 3.6, 95%CI = 2.30–5.76). Collagen biomarkers were predictive of shorter OS in patients with mCRC. This supports that collagen- and CAF biology is important in CRC.

Download Full-text